ZA200204019B - Combination treatment for alcoholism and alcohol dependence. - Google Patents

Combination treatment for alcoholism and alcohol dependence.

Info

Publication number
ZA200204019B
ZA200204019B ZA200204019A ZA200204019A ZA200204019B ZA 200204019 B ZA200204019 B ZA 200204019B ZA 200204019 A ZA200204019 A ZA 200204019A ZA 200204019 A ZA200204019 A ZA 200204019A ZA 200204019 B ZA200204019 B ZA 200204019B
Authority
ZA
South Africa
Prior art keywords
alcoholism
combination treatment
alcohol dependence
dependence
alcohol
Prior art date
Application number
ZA200204019A
Other languages
English (en)
Inventor
Howard Harry Ralph Jr
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200204019B publication Critical patent/ZA200204019B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200204019A 2001-05-23 2002-05-21 Combination treatment for alcoholism and alcohol dependence. ZA200204019B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29308801P 2001-05-23 2001-05-23

Publications (1)

Publication Number Publication Date
ZA200204019B true ZA200204019B (en) 2003-11-21

Family

ID=23127615

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200204019A ZA200204019B (en) 2001-05-23 2002-05-21 Combination treatment for alcoholism and alcohol dependence.

Country Status (11)

Country Link
US (2) US20030130322A1 (cs)
EP (1) EP1262196A3 (cs)
JP (1) JP2002370975A (cs)
KR (1) KR20020090153A (cs)
CN (1) CN1386503A (cs)
AU (1) AU4068602A (cs)
CA (1) CA2386740A1 (cs)
HU (1) HUP0201722A2 (cs)
NZ (1) NZ519032A (cs)
PL (1) PL354110A1 (cs)
ZA (1) ZA200204019B (cs)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096201A1 (en) * 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US8758443B2 (en) 2005-05-06 2014-06-24 Titan Spine, Llc Implants with integration surfaces having regular repeating surface patterns
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
WO2007064586A1 (en) * 2005-11-28 2007-06-07 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US8088786B2 (en) 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
MX343867B (es) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
JP2010513569A (ja) * 2006-12-19 2010-04-30 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果
CA2716498C (en) 2008-02-28 2020-12-22 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
KR20120124423A (ko) 2010-01-11 2012-11-13 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
IL278149B2 (en) 2010-07-02 2024-03-01 Univ Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
WO2013036721A1 (en) 2011-09-09 2013-03-14 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
US9633575B2 (en) 2012-06-06 2017-04-25 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
CN114588467B (zh) * 2022-04-01 2022-11-29 广州蓝仕威克医疗科技有限公司 一种基于气体混合比例供气解决酒精中毒的方法及呼吸机
CN115671107B (zh) * 2022-12-29 2023-04-04 文韬创新药物研究（北京）有限责任公司 用于解酒的复方药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923283B (en) * 1991-05-29 1993-01-27 Akzo Nv Phenoxyphenyl derivatives
CA2197554A1 (en) * 1994-09-19 1996-03-28 The Du Pont Merck Pharmaceutical Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US5948807A (en) * 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
CA2364718C (en) * 1999-02-23 2006-07-11 Pfizer Products Inc. Monoamine reuptake inhibitors for treatment of cns disorders
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
YU21602A (sh) * 1999-10-13 2005-06-10 Pfizer Products Inc. Derivati biaril etra korisni kao inhibitori ponovnog podizanja monoamina

Also Published As

Publication number Publication date
JP2002370975A (ja) 2002-12-24
CA2386740A1 (en) 2002-11-23
AU4068602A (en) 2002-12-05
HU0201722D0 (cs) 2002-07-29
PL354110A1 (en) 2002-12-02
US20040162316A1 (en) 2004-08-19
EP1262196A3 (en) 2002-12-18
KR20020090153A (ko) 2002-11-30
CN1386503A (zh) 2002-12-25
NZ519032A (en) 2003-10-31
HUP0201722A2 (hu) 2003-07-28
EP1262196A2 (en) 2002-12-04
US20030130322A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
ZA200204020B (en) Use of anti-CTLA-4-antibodies.
MXPA03009647A (es) Heterociclildicarbamidas como inhibidores de caspasa.
AU2001260513A1 (en) Microcapsule well treatment
ZA200208561B (en) Hydraulischer druckverstarker.
ZA200204019B (en) Combination treatment for alcoholism and alcohol dependence.
ZA200201866B (en) Valve device.
GB0113493D0 (en) Parking aid
GB2392483B (en) Work-assembling auxiliary device, and work-assembling process
MXPA03005286A (es) METODO Y APARATO PARA SUPERVISAR PULSACION DE INSTALACION DE ORDEnA.
MXPA03008139A (es) Fluoralcoxifenilsulfonilureas sustituidas.
EP1422743A4 (en) TREATMENT SYSTEM
GB2380037B (en) Recognition system
GB0127384D0 (en) Well treatment system
ZA200204018B (en) Combination treatment for depression and anxiety.
GB2376239B (en) Cask treatment
GB2389165B (en) Valve system
ZA200204985B (en) Activated rec-D-hydantoinases.
GB0007510D0 (en) D.o.t.t.s
GB0130694D0 (en) Treatment
IL149703A0 (en) Combination treatment for alcoholism and alcohol dependence
GB0105446D0 (en) S.s.h.p.s
HU0104096D0 (en) Bottled wine-and-soda
GB0116210D0 (en) P.c.o
GB0118494D0 (en) P.c.o.
ZA200206978B (en) Gravestone.